- call +1-201-465-4211
- email sales@mrinsights.biz
Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.
Scope of the Report:
This report focuses on the Postmenopausal Vaginal Atrophy Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Postmenopausal Vaginal Atrophy Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Actavis plc
Bionovo, Inc.
Endoceutics, Inc.
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceuticals Ltd.
Therapeutics MD, Inc.
Shionogi & Company
Allergan plc
Shionogi & Co. Ltd.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Premarin
Vagifem
Estrace
Estring
Femring
Market Segment by Applications, can be divided into
Vaginal Gels
Creams
Tablets
Rings
Patches
There are 15 Chapters to deeply display the global Postmenopausal Vaginal Atrophy Drugs market.
Chapter 1, to describe Postmenopausal Vaginal Atrophy Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Postmenopausal Vaginal Atrophy Drugs, with sales, revenue, and price of Postmenopausal Vaginal Atrophy Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Postmenopausal Vaginal Atrophy Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Postmenopausal Vaginal Atrophy Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Postmenopausal Vaginal Atrophy Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Postmenopausal Vaginal Atrophy Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Premarin
1.2.2 Vagifem
1.2.3 Estrace
1.2.4 Estring
1.2.5 Femring
1.3 Market Analysis by Applications
1.3.1 Vaginal Gels
1.3.2 Creams
1.3.3 Tablets
1.3.4 Rings
1.3.5 Patches
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Actavis plc
2.1.1 Business Overview
2.1.2 Postmenopausal Vaginal Atrophy Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Bionovo, Inc.
2.2.1 Business Overview
2.2.2 Postmenopausal Vaginal Atrophy Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Endoceutics, Inc.
2.3.1 Business Overview
2.3.2 Postmenopausal Vaginal Atrophy Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novo Nordisk A/S
2.4.1 Business Overview
2.4.2 Postmenopausal Vaginal Atrophy Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Pfizer Inc.
2.5.1 Business Overview
2.5.2 Postmenopausal Vaginal Atrophy Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Teva Pharmaceuticals Ltd.
2.6.1 Business Overview
2.6.2 Postmenopausal Vaginal Atrophy Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Therapeutics MD, Inc.
2.7.1 Business Overview
2.7.2 Postmenopausal Vaginal Atrophy Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Shionogi & Company
2.8.1 Business Overview
2.8.2 Postmenopausal Vaginal Atrophy Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Allergan plc
2.9.1 Business Overview
2.9.2 Postmenopausal Vaginal Atrophy Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Shionogi & Co. Ltd.
2.10.1 Business Overview
2.10.2 Postmenopausal Vaginal Atrophy Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Postmenopausal Vaginal Atrophy Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Postmenopausal Vaginal Atrophy Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Postmenopausal Vaginal Atrophy Drugs Market Analysis by Regions
4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
4.5 South America Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
5 North America Postmenopausal Vaginal Atrophy Drugs by Countries
5.1 North America Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
6 Europe Postmenopausal Vaginal Atrophy Drugs by Countries
6.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
6.3 UK Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
6.4 France Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs by Countries
7.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
7.5 India Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
8 South America Postmenopausal Vaginal Atrophy Drugs by Countries
8.1 South America Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Postmenopausal Vaginal Atrophy Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Countries
9.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2013-2018)
10 Global Postmenopausal Vaginal Atrophy Drugs Market Segment by Type
10.1 Global Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Type (2013-2018)
10.2 Premarin Sales Growth and Price
10.2.1 Global Premarin Sales Growth (2013-2018)
10.2.2 Global Premarin Price (2013-2018)
10.3 Vagifem Sales Growth and Price
10.3.1 Global Vagifem Sales Growth (2013-2018)
10.3.2 Global Vagifem Price (2013-2018)
10.4 Estrace Sales Growth and Price
10.4.1 Global Estrace Sales Growth (2013-2018)
10.4.2 Global Estrace Price (2013-2018)
10.5 Estring Sales Growth and Price
10.5.1 Global Estring Sales Growth (2013-2018)
10.5.2 Global Estring Price (2013-2018)
10.6 Femring Sales Growth and Price
10.6.1 Global Femring Sales Growth (2013-2018)
10.6.2 Global Femring Price (2013-2018)
11 Global Postmenopausal Vaginal Atrophy Drugs Market Segment by Application
11.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2013-2018)
11.2 Vaginal Gels Sales Growth (2013-2018)
11.3 Creams Sales Growth (2013-2018)
11.4 Tablets Sales Growth (2013-2018)
11.5 Rings Sales Growth (2013-2018)
11.6 Patches Sales Growth (2013-2018)
12 Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2023)
12.1 Global Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Postmenopausal Vaginal Atrophy Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2023)
12.2.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2023)
12.2.4 South America Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2023)
12.3 Postmenopausal Vaginal Atrophy Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Type (2018-2023)
12.4 Postmenopausal Vaginal Atrophy Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Postmenopausal Vaginal Atrophy Drugs Picture
Table Product Specifications of Postmenopausal Vaginal Atrophy Drugs
Figure Global Sales Market Share of Postmenopausal
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
